Tech Company Financing Transactions
Amylyx Pharmaceuticals Funding Round
Private investors participated in a $13 million capital raise for Amylyx Pharmaceuticals. The round was announced on 11/21/2018.
Transaction Overview
Company Name
Announced On
11/21/2018
Transaction Type
Debt
Amount
$12,978,100
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 32 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
43 Thorndike St.
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Undisclosed
Website
Email Address
Overview
Amylyx is an IND-enabling stage biopharmaceutical company dedicated to providing innovative, disease-modifying solutions for neurodegenerative diseases. We have a highly creative and motivated team focused on streamlined clinical development and drug discovery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joshua Cohen
Chief Executive Officer
Justin Klee
Chief Financial Officer
James Frates
Chief Medical Officer
Patrick Yeramian
Chief Scientific Officer
Kent Leslie
VP - Bus. Development
Margaret Olinger
VP - Human Resources
Debra Canner
Browse more venture capital transactions:
Prev: 11/21/2018: Green Mountain CBD venture capital transaction
Next: 11/22/2018: Workable venture capital transaction
Share this article
About Database of VC Transactions
We record every notable VC transaction. VC transactions reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs